Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up by A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska

Get full text